RepliCel Life Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RepliCel Life Sciences generated cash of -$1,414,083, which is less than the previous year. Cash used in financing activities reached the amount of $1,060,218 last year. Net change in cash is therefore -$353,865.
Cash Flow
| 2014 | -4.44M | -1.51M | 4.53M |
|---|---|---|---|
| 2015 | -4.36M | 1.49M | 2.50M |
| 2016 | -3.54M | -1.45M | 4.87M |
| 2017 | -5.38M | 1.45M | 4.37M |
| 2018 | -386.09K | 0 | 2.30M |
| 2019 | -2.78M | -28.75K | 415.99K |
| 2020 | -765.20K | 11.5K | 764.13K |
| 2021 | -2.51M | 0 | 2.70M |
| 2022 | -1.40M | 0 | 1.60M |
| 2023 | -1.41M | 0 | 1.06M |
RP.V Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 413.02K | 221.18K | 34.36K | 23.92K | 2.41M | 497.09K | 60.75K | 175.79K | 535.11K | 1.95M |
Operating activities | ||||||||||
Net income | -311.73K | -743.22K | -4.07M | -1.58M | -3.00M | -2.76M | -6.01M | -4.27M | -5.04M | -5.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.47K | 839 | 1.14K | 1.57K | 2.16K | 2.99K | 4.15K | 5.78K | 6.97K | 7.60K |
Stock-based compensation expense | 241.48K | 69.05K | 471.75K | 3.39K | 26.27K | 0 | 115.8K | 826.30K | 131.71K | 784.39K |
| Deferred income tax benefit | 241.48K | 69.05K | 471.75K | 3.39K | 26.27K | 0 | 115.8K | 826.30K | 131.71K | 784.39K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -20.92K | 2.37K | -11.71K | 32.98K | -354.69K | 17.51K | -40.24K | 3.29K | 0 |
Inventories | 0 | -300.23K | 298.51K | -846.48K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 321.16K | -300.89K | 858.20K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -1.41M | -1.40M | -2.51M | -765.20K | -2.78M | -386.09K | -5.38M | -3.54M | -4.36M | -4.44M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -28.75K | 0 | 0 | -1.45M | 0 | -1.5M |
Investments In Property Plant And Equipment | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.19K | -10.16K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 11.5K | -28.75K | 0 | 1.45M | -1.45M | 1.49M | -1.51M |
Financing activities | ||||||||||
Common Stock Issued | 1.01M | 1.60M | 1.8K | 656.84K | 0 | 2.56M | 4.32M | 4.84M | 2.64M | 3.99M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -47.29K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.06M | 1.60M | 2.70M | 764.13K | 415.99K | 2.30M | 4.37M | 4.87M | 2.50M | 4.53M |
Net Change In Cash | -353.86K | 191.83K | 186.82K | 10.43K | -2.39M | 1.92M | 436.34K | -115.03K | -359.32K | -1.42M |
Cash at end of period | 59.16K | 413.02K | 221.18K | 34.36K | 23.92K | 2.41M | 497.09K | 60.75K | 175.79K | 535.11K |